You are here

Clot Ingestion System Receives Breakthrough Device Designation Status

Novel Catheter-based Technology for Treating Acute Ischemic Stroke

Perfuze has been granted breakthrough device designation by the FDA for its Millipede CIS technology, designed to remove clots from the brain following an acute ischemic stroke.

According to the World Health Organization, stroke is the second leading global cause of death and a leading cause of disability. An ischemic stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow. Perfuze’s technology aims to provide superior clinical outcomes in shorter procedural times, resulting in safe, cost-effective therapy.

Perfuze, which was founded in 2018, announced in January 2019 that it had raised more than $3 million in a seed round led by Earlybird, a venture capitalist company, with participation by an Irish syndicate of med-tech veterans and stroke physicians.

“Perfuze has a technology with the potential to significantly improve outcomes for stroke patients,” said Earlybird partner John Yianni. “We are delighted to offer our financial and commercial support in helping this exciting company grow and get its life-saving technology to market.”

Source:, Aug. 7, 2019;

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs